Kura Oncology
- Country
- ๐บ๐ธUnited States
- Ownership
- Public
- Established
- 2014-01-01
- Employees
- 142
- Market Cap
- $1.5B
- Website
- http://www.kuraoncology.com
- Introduction
Kura Oncology, Inc. operates as a clinical-stage biopharmaceutical company, which engages in the research and development of medicines for the treatment of cancer. Its pipeline includes Tipifarnib, which is a Farnesyl transferase inhibitor for HRAS Mutant Solid Tumors, Chronic Myelomonocytic Leukemia, KO-947, which is an ERK inhibitor for MAPK Pathway Tumors...
Safety and Efficacy of Tipifarnib in Head and Neck Cancer With HRAS Mutations and Impact of HRAS on Response to Therapy
- Conditions
- Interventions
- First Posted Date
- 2018-10-25
- Last Posted Date
- 2024-06-21
- Lead Sponsor
- Kura Oncology, Inc.
- Target Recruit Count
- 296
- Registration Number
- NCT03719690
- Locations
- ๐บ๐ธ
University of Southern California Norris Comprehensive Cancer Center, Los Angeles, California, United States
๐บ๐ธUCLA - Jonsson Comprehensive Cancer Center, Los Angeles, California, United States
๐บ๐ธUniversity of Chicago, Chicago, Illinois, United States
First-in-Human Study of KO-947 in Non-Hematological Malignancies
- First Posted Date
- 2017-02-13
- Last Posted Date
- 2021-09-20
- Lead Sponsor
- Kura Oncology, Inc.
- Target Recruit Count
- 61
- Registration Number
- NCT03051035
- Locations
- ๐บ๐ธ
Mayo Clinic, Rochester, Minnesota, United States
๐ช๐ธSTART Madrid-HM CIOCC, Madrid, Spain
๐บ๐ธMemorial Sloan Kettering Cancer Center, New York, New York, United States
Tipifarnib in Subjects With Chronic Myelomonocytic Leukemia, Other MDS/MPN, and Acute Myeloid Leukemia
- First Posted Date
- 2016-06-21
- Last Posted Date
- 2024-07-17
- Lead Sponsor
- Kura Oncology, Inc.
- Target Recruit Count
- 44
- Registration Number
- NCT02807272
- Locations
- ๐บ๐ธ
Johns Hopkins University, Baltimore, Maryland, United States
๐บ๐ธUniversity of Pennsylvania Hospital, Philadelphia, Pennsylvania, United States
๐บ๐ธMayo Clinic Florida, Jacksonville, Florida, United States
Tipifarnib in Subjects With Myelodysplastic Syndromes
- First Posted Date
- 2016-05-20
- Last Posted Date
- 2024-07-31
- Lead Sponsor
- Kura Oncology, Inc.
- Target Recruit Count
- 16
- Registration Number
- NCT02779777
- Locations
- ๐บ๐ธ
Dana-Farber Cancer Institute, Boston, Massachusetts, United States
๐บ๐ธColumbia University Medical Center, New York, New York, United States
Investigation of Tipifarnib in Treatment of Subjects With Peripheral T-Cell Lymphoma (PTCL) That Have Not Responded to Standard Therapy
- Conditions
- Interventions
- First Posted Date
- 2015-06-08
- Last Posted Date
- 2024-06-26
- Lead Sponsor
- Kura Oncology, Inc.
- Target Recruit Count
- 65
- Registration Number
- NCT02464228
- Locations
- ๐ช๐ธ
Hospital Universitari Vall d'Hebron, Barcelona, Spain
๐บ๐ธStanford University Medical Center, Palo Alto, California, United States
๐ช๐ธInstitut Catala d'Oncologia de Girona, Girona, Spain
Phase II Study of Tipifarnib in Squamous Head and Neck Cancer With HRAS Mutations
- First Posted Date
- 2015-03-10
- Last Posted Date
- 2024-07-11
- Lead Sponsor
- Kura Oncology, Inc.
- Target Recruit Count
- 63
- Registration Number
- NCT02383927
- Locations
- ๐บ๐ธ
Wihship Cancer Institute of Emory University, Atlanta, Georgia, United States
๐บ๐ธOklahoma University Health Sciences Center, Oklahoma City, Oklahoma, United States
๐บ๐ธThe University of Texas MD Anderson Cancer Center, Houston, Texas, United States